CD274 and non-small cell lung carcinoma: In conclusion, pembrolizumab monotherapy improved clinical outcomes with fewer AEs than chemotherapy in patients with treatment-naive and previously treated PD-L1‒positive, advanced or metastatic NSCLC, including those with treated, stable brain metastases.